# Calcitonin

```text
DRUG INFORMATION

  ADULT
    - Ensure adequate calcium and vitamin D intake ( 2.3 , 2.5 ) 2.1 Paget’s Disease of
      Bone The recommended dose of calcitonin salmon injection for treatment of
      symptomatic Paget's disease of bone is 100 International Units (0.5 mL) per day
      administered subcutaneously or intramuscularly.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'dosage and
      administration', retrieved 2026-08-29
    - If the response remains unsatisfactory after two more days, the dose may be
      further increased to a maximum of 8 International Units/kg every 6 hours. 2.3
      Postmenopausal Osteoporosis The recommended dose of calcitonin salmon injection
      for treatment of postmenopausal osteoporosis in women greater than 5 years
      postmenopause is 100 International Units (0.5 mL) per day administered
      subcutaneously or intramuscularly.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'dosage and
      administration', retrieved 2026-08-29
    - If the volume of calcitonin salmon injection to be injected exceeds 2 mL,
      intramuscular injection is preferable and the total dose should be distributed
      across multiple sites of injection.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Safety and effectiveness in pediatric patients have not been established.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'pediatric use',
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for calcitonin (Calcitonin
      Salmon), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for calcitonin (Calcitonin
      Salmon), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary There are no studies with calcitonin salmon injection in pregnant
      women to inform a drug associated risk for birth defects or miscarriage.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'pregnancy',
      retrieved 2026-08-29
    - In an animal reproduction study, subcutaneous administration of calcitonin salmon
      to pregnant rabbits during organogenesis at 4 to 18 times the recommended
      parenteral human dose caused a decrease in fetal birth weights.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'pregnancy',
      retrieved 2026-08-29
    - No adverse developmental outcome was observed in the rat with subcutaneous
      administration of calcitonin salmon at 9 times the recommended human parenteral
      dose based on body surface area (see D ata ).
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Risk Summary There is no information on the presence of calcitonin salmon in human
      milk, the effects on the breastfed child, or the effects on milk production.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'nursing
      mothers', retrieved 2026-08-29
    - Calcitonin has been shown to inhibit lactation in rats.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'nursing
      mothers', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for calcitonin salmon injection and any potential
      adverse effects on the breastfed infant from calcitonin salmon injection or from
      the underlying maternal condition.
      Source: US FDA label for calcitonin (Calcitonin Salmon), section 'nursing
      mothers', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)